Procentdelen af patienter med bivirkninger var næsten ens i de to behandlingsgrupper (26, 6% i Xeomin- gruppen og 26, 0% i Botox- gruppen).
An almost identical percentage of patients in both treatment groups reported AEs (26.6% in the Xeomin group and 26.0% in the Botox group).